• Caribou Biosciences to Participate in Upcoming Investor Conferences

    ソース: Nasdaq GlobeNewswire / 01 2 2023 16:05:00   America/New_York

    BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to participate in the following investor conferences:

    • Guggenheim Oncology Conference 2023, New York City
      February 9, 2023, 10:45 am EST
      Webcast
    • SVB Securities Global Biopharma Conference, virtual
      February 14, 2023, 5:00 pm EST
      Webcast
    • Citi's 2023 Oncology Leadership Summit, virtual
      February 22, 2023, 2:00 pm EST
      Webcast to be made available on Events page

    For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.

    About Caribou’s Novel Next-Generation CRISPR Platform
    CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

    About Caribou Biosciences, Inc.
    Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.

    For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

    “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

    Caribou Biosciences Contacts:

    Investors:
    Amy Figueroa, CFA
    afigueroa@cariboubio.com

    Media:
    Peggy Vorwald, Ph.D.
    pvorwald@cariboubio.com

    Investors and Media:
    Elizabeth Wolffe, Ph.D., and Sylvia Wheeler
    Wheelhouse LSA
    lwolffe@wheelhouselsa.com
    swheeler@wheelhouselsa.com


    Primary Logo

シェアする